CoronavirusNCT04305574
Social Media Use During COVID-19
An observational study of Coronavirus and Depression, run by Jean Liu at 1 site in Singapore.
Trial summary
The investigators plan to conduct a cross-sectional survey to examine how social media use during COVID-19 relates to: (1) information management, (2) assessment of the situation, and (3) affect. Read more about this study
- Who is it for?
- Ages 21 years and olderHealthy volunteers can take part
- Conditions the study is for
- Coronavirus, Depression, Anxiety
- What is being tested?
- Use of social media during COVID-19
- Type of treatment
- Lifestyle or therapy programme
- How many people
- 1,145 participants
- Where
- 1 siteSingapore
- Study dates
- 7 Mar 2020to 21 Apr 2020
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 21 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Study population: Representative sample of the Singapore population
Who may be able to join
- At least 21 years
- Has stayed in Singapore for at least 2 years
Who cannot join
- Below 21 years
- Has stayed in Singapore for less than 2 years
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Getting it Right: Towards Responsible Social Media Use During a Pandemic
The investigators plan to conduct a cross-sectional survey to examine how social media use during COVID-19 relates to: (1) information management, (2) assessment of the situation, and (3) affect.
- Conditions
- Coronavirus, Depression, Anxiety, Stress
- Being tested
- Use of social media during COVID-19
- Keywords
- COVID-19, Social media, Communication
- Medical subject headings
- Coronavirus Infections, Depression, Anxiety Disorders, COVID-19, Communication
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Use of social media during COVID-19Behavioural
Also called WhatsApp
Participants' self-reported use of an official WhatsApp channel to receive and share news about COVID-19
| Study group | Role | What they receive |
|---|---|---|
| Community sample | We plan to recruit a representative sample of the Singapore population. Receives: Behavioral: Use of social media during COVID-19 |
What is being measured
The primary outcome is the main question the study is designed to answer.
Depression, Anxiety and Stress Scale
21-item validated scale assessing symptoms of depression, anxiety, and stress (DASS-21): Min score = 0, Max score = 21; higher score indicates a worse outcome
Measured: Single measurement (upon study enrolment)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted12 Mar 2020
- Study start7 Mar 2020
- Primary completion21 Apr 2020
- Study completion21 Apr 2020
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for CoronavirusStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Cross-sectional
- Enrolment
- 1,145 participants (actual)
Sponsor and investigators
- Lead sponsor
- Jean Liu
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor-investigator, Jean Liu, Yale-NUS College
- Investigators
- Jean Liu, PhD, Principal investigator, Yale-NUS College
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04305574
- Sponsor's protocol ID
- 2020-CERC-001
- Status last verified
- Jul 2020
- First submitted
- 8 Mar 2020
- Last updated
- 7 Jul 2020
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: Due to stipulations by the Institutional Review Board, data cannot be shared.
Publications
Liu JCJ, Tong EMW. The Relation Between Official WhatsApp-Distributed COVID-19 News Exposure and Psychological Symptoms: Cross-Sectional Survey Study. J Med Internet Res. 2020 Sep 25;22(9):e22142. doi: 10.2196/22142.
PubMed 32877349
Study at a glance
From the registry record, last updated by the sponsor on 7 Jul 2020. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Getting it Right: Towards Responsible Social Media Use During a Pandemic
- ClinicalTrials.gov ID
- NCT04305574
- Acronym / sponsor ID
- 2020-CERC-001
- Conditions
- Coronavirus, Depression, Anxiety, Stress
- Keywords
- COVID-19, Social media, Communication
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 1,145 participants (actual)
- Lead sponsor
- Jean LiuUniversity, hospital or other
- Study start
- 7 Mar 2020 (actual)
- Primary completion
- 21 Apr 2020 (actual)
- Study completion
- 21 Apr 2020 (actual)
- First posted
- 12 Mar 2020 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The investigators plan to conduct a cross-sectional survey to examine how social media use during COVID-19 relates to: (1) information management, (2) assessment of the situation, and (3) affect.
Study design
- Observational model
- Cohort
- Time perspective
- Cross-sectional
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Community sample | – | Behavioral: Use of social media during COVID-19We plan to recruit a representative sample of the Singapore population. |
Who may qualify
- Ages
- 21 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
- Study population
- Representative sample of the Singapore population
Key inclusion criteria (2 listed)
- At least 21 years
- Has stayed in Singapore for at least 2 years
Key exclusion criteria (2 listed)
- Below 21 years
- Has stayed in Singapore for less than 2 years
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Use of social media during COVID-19Also: WhatsAppParticipants' self-reported use of an official WhatsApp channel to receive and share news about COVID-19 | Behavioural | Community sample |
Primary outcome
Depression, Anxiety and Stress Scale
Time frame: Single measurement (upon study enrolment)
21-item validated scale assessing symptoms of depression, anxiety, and stress (DASS-21): Min score = 0, Max score = 21; higher score indicates a worse outcome
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 7 Jul 2020.
- Derived from this study: PubMed 32877349Liu JCJ, Tong EMW. The Relation Between Official WhatsApp-Distributed COVID-19 News Exposure and Psychological Symptoms: Cross-Sectional Survey Study. J Med Internet Res. 2020 Sep 25;22(9):e22142. doi: 10.2196/22142.
- Individual participant dataSharing planned: No. Due to stipulations by the Institutional Review Board, data cannot be shared.
Related trials for Coronavirus
Not yet recruitingPhase 1
A Safety, Reactogenicity and Immunogenicity Trial of RVX-sCPD9 Booster Intranasal COVID-19 Vaccine
COVID -19
Not yet recruitingPhase 3
Dapagliflozin for Long COVID Syndrome
COVID - 19, Long COVID Syndrome
RecruitingPhase 1
A Safety and Immunogenicity Trial of OCU500, ChAd36 Vector Encoding SARS-CoV-2 Spike Vaccine Via Intranasal and Inhalational Routes in Previously Vaccinated Adults
COVID-19
Active, not recruitingObservational study
Analysis of Coronavirus Disease 19 (COVID-19) Convalescent Plasma
Asymptomatic COVID-19 Infection Laboratory-Confirmed, Symptomatic COVID-19 Infection Laboratory-Confirmed
Not yet recruitingPhase 1
Phase I Open-Label Safety Trial of Pembrolizumab for Neurological Post- Acute Sequelae of SARS-CoV-2 (PD1-PASC I)
Post-Acute COVID-19 Syndrome
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Jean Liu, PhD principal investigator
Yale-NUS College
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Coronavirus and Depression, run by Jean Liu at 1 site in Singapore.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 7 Jul 2020. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Singapore. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Depression, Anxiety and Stress Scale (time frame: Single measurement (upon study enrolment)). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT04305574, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 7 Jul 2020.